Nicole Lamanna, MD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Octapharma
    Topic:
    CLL
    Date added:
    03/12/2024
    Date updated:
    03/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Oncternal
    Topic:
    CLL
    Date added:
    03/12/2024
    Date updated:
    03/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Aptitude Health
    Topic:
    CLL
    Date added:
    03/12/2024
    Date updated:
    03/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    BioAscend
    Topic:
    CLL
    Date added:
    03/12/2024
    Date updated:
    03/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Clinical Care Options
    Topic:
    CLL
    Date added:
    03/12/2024
    Date updated:
    03/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Curio
    Topic:
    CLL
    Date added:
    03/12/2024
    Date updated:
    03/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    DAVA Oncology
    Topic:
    CLL
    Date added:
    03/12/2024
    Date updated:
    03/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    OncLive
    Topic:
    CLL
    Date added:
    03/12/2024
    Date updated:
    03/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    PER
    Topic:
    CLL
    Date added:
    03/12/2024
    Date updated:
    03/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Peerview
    Topic:
    CLL
    Date added:
    03/12/2024
    Date updated:
    03/13/2024

Pages

Return to Upstate New York Hematology & Hematologic Oncology Conference: Updates from the 65th ASH Annual Meeting